Ethicon launches next-gen surgical stapler

The next-gen Echelon 3000 surgical stapler [Image courtesy of Johnson & Johnson’s Ethicon]Johnson & Johnson’s Ethicon today announced the U.S. launch of its next-gen Echelon 3000 stapler.

The Echelon 3000 is digitally-enabled and provides surgeons with simple, one-handed powered articulation, according to the Johnson & Johnson (NYSE:JNJ) company.

The surgical stapler’s creators designed it with 39% greater jaw aperture and a 27% greater articulation span. The idea was to give surgeons better access and control over each transection. The software then provides real-time haptic and audible device feedback so that surgeons can make critical adjustments during procedures.

“Surgical complications often stem from difficult-to-access anatomy and compromised tissue, which this next generation Echelon stapler is specifically designed to address,” said Tom O’Brien, worldwide president of Endomechanical at Ethicon.

<…
Read more
  • 0

FDA clears J&J’s Ethicon’s Monarch surgical robot for urology procedures

[Image from Auris Health’s website]Johnson & Johnson MedTech (NYSE:JNJ) company Ethicon announced today that its Monarch robotic surgery platform received FDA 510(k) clearance.

Ethicon’s Auris Health subsidiary received the FDA clearance for Monarch for endourological procedures, making it the first and only multispecialty, flexible robotic solution for use in both bronchoscopy and urology.

The company said in a news release that it designed the Monarch robot-assisted surgical platform to enable urologists to reach and visualize areas within the kidney with precision and control. The system offers one platform for supporting both ureteroscopic and percutaneous nephrolithotomy (PCNL) procedures.

“Monarch reduces the complexity of gaining high-quality percutaneous access and aids stone clearance efficiency through simultaneous fragmentation and suctioning of stones with robotic assistance,” University of Southern Cali…

Read more
  • 0

Johnson & Johnson must face former Auris Health shareholders’ fraud lawsuit

[Image from Unsplash]A Delaware judge has denied Johnson & Johnson’s motions to dismiss a fraud lawsuit filed by former shareholders of Auris Health, who alleged that J&J executives misrepresented their intentions for the robotic surgery company when they acquired it for $3.4 billion in 2019.

Acting as the representative of the former Auris shareholders, Fortis Advisors sued last year after the medtech giant released reserves related to the additional $2.35 billion in milestone payments that were part of the agreement.

J&J, its Ethicon subsidiary and top corporate officers violated the merger agreement and made false promises during negotiations, according to the lawsuit.

Vice Chancellor Lori W. Will in Delaware, in a December 13 order, allowed more than half of Fortis Advisors counts against J&J to proceed, though she dismissed claims against individual J&J executives on jurisdictional grounds.

Surgical robotics is a hot sp…

Read more
  • 0

DTW Weekly Podcast – Digging Deeper into Cleerly Health $43 million round

In this week’s DeviceTalks Weekly Podcast, we talk with Dr. James Min, the founder and CEO of Cleerly Health, a potentially disruptive diagnostics company that raised $43 million last week. Dr. Min explains how Cleerly Health formed from his work at Weill Cornell Medicine. But, more importantly for entrepreneurs and executives, he walks listeners through the steps he took to prepare for the fund-raising. In our next episode we’ll talk with two VCs who invested in the company to hear why Cleerly’s pitch worked.

We also talk with Jeremy Maniak, the CEO of Minnetronix, which is celebrating its 25th year in business. Maniak shares why medtech is such a draw for quality engineers who want to work for a purpose and work with the top technology. He also takes us through the process that led to Minnetronix creating its own medical device. Maniak, an electrical engineer himself, says Minnetronix will partner with OEMs to sell the device.

Chris Newmarke…

Read more
  • 0

Ethicon launches curved jaw tissue sealer

[Image from Ethicon]Ethicon — part of Johnson & Johnson (NYSE:JNJ) — announced today that it launched the Enseal X1 curved jaw tissue sealer.

Cincinnati-based Ethicon developed the Enseal as a new advanced bipolar energy device designed to increase procedural efficiency and provide stronger sealing and better access to more tissue than Medtronic’s LigaSure Maryland, according to a news release.

Indications for the device include colorectal, gynecological, bariatric surgery and thoracic procedures. It includes separate seal and cut capabilities, a 360-degree continuous shaft rotation that enables easy access to targeted tissue. Ethicon’s adaptive tissue technology allows the device to continuously sense changes in the condition of tissue and respond accordingly with the optimal amount of energy to minimize lateral thermal spread.

Enseal X1 curved jaw marks the first of a series of new advanced laparoscopic bipolar devices set to launch from E…

Read more
  • 0

N.J. appeals court tosses $83M pelvic mesh verdicts against J&J, Bard

A New Jersey appeals court yesterday threw out jury verdicts totaling $83 million in separate pelvic mesh lawsuits against Johnson & Johnson’s  (NYSE:JNJ) Ethicon division and Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard.

In both cases, Bergen County, N.J. judges erred by disallowing evidence showing that each company’s mesh product had received FDA 510 (k) clearance, according to the appeals court panel.

In the case against J&J’s Ethicon, a jury had awarded Elizabeth and Tadeusz Hrymoc $5 million in compensatory damages and $10 million in punitive damages after finding the companies liable for violating New Jersey laws on defective design of their ProLift pelvic mesh and failing to warn patients of product risk.

The jury in the case brought by Mary McGinnis and Thomas Walsh McGinnis found Bard liable for design and failure-to-warn defects under the product liability laws of North Carolina, the plaintiffs’ home state, …

Read more
  • 0

DTW Podcast: Zimmer Biomet slims, Corza Medical grows in pursuit of grabbing market share

In this week’s DeviceTalks Weekly Podcast, Rich Newitter, managing director at SVB Leerink, says Zimmer Biomet’s decision to spin out its spinal and dental business will accelerate its already impressive market share grab in its core orthopedics industry.

Dewitter says CEO Bryan Hanson brings a tried-and-true diversification model used by companies like his former employer, Covidien. The spinout of the spinal and dental businesses into a NewCo will allows the company to focus more resources on selling knee and hip implants as well as building out an impressive robotics franchise and a potentially sector-leading line of digital tools and sensors.

“Zimmer has effectively gone from a share loser for almost a decade leading up to when Bryan Hanson took over to a share-taking position,” he said in an interview with Chris Newmarker, executive editor of life sciences. “This most recent quarter, their share gains have widened quite dramatically.”

In …

Read more
  • 0

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tool supplier that its executive chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass., to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company NuVasive (NSDQ:NUVA) and diagnostic company Life Technologies, said management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost mono…

Read more
  • 0

Corza Medical set to take on “almost monopolistic” surgical giants

Corza Medical, a new venture backed by the financial firepower of private equity giant GTCR, is looking to build a surgical tools supplier that its Executive Chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space.

To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic knives. Corza will use this beachhead in Westwood, Mass. to build a pipeline of acquired assets including TachoSil, a surgical patch product line Corza had acquired from Takeda Pharmaceuticals last year.

In an interview with the DeviceTalks Weekly podcast, Lucier, the former CEO of spinal company Nuvasive and diagnostic leader Life Technologies, says management believes “there is an opening for a pretty good-sized surgical tools and technologies company to compete against the Ethicons and the Medtronics of the world.”

Lucier said the two Goliaths have reached a size that makes them “almost monopolistic …

Read more
  • 0

J&J’s Ethicon touts surgical stapler study

The Echelon powered stapler with gripping surface technology (GST) [Image courtesy of Ethicon]

Ethicon — part of Johnson & Johnson (NYSE:JNJ) — is highlighting new study results in which its Echelon powered stapler with gripping surface technology (GST) had a lower rate of bleeding-related complications than a competing Medtronic product.

Ethicon funded the peer-reviewed study, which appears online in Medical Devices: Evidence and Research. The study compared the Echelon stapler with Medtronic’s Signia stapling system with Tri-Staple among patients undergoing laparoscopic sleeve gastrectomy for obesity.

Get the full story on our sister site Medical Design & Outsourcing. 

Read more
  • 0

J&J’s Ethicon wins FDA breakthrough nod for microwave ablation tech

Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon announced that it received FDA breakthrough device designation for its microwave ablation technology.

The transbronchial microwave ablation technology, which is currently under development, utilizes robotic-assisted bronchoscopy. Johnson & Johnson’s acquisitions of NeuWave Medical and Auris Health allowed the company to bring the robotic surgical and microwave ablation technology together to develop the new breakthrough device, according to a news release.

Ethicon’s NeuWave microwave ablation system treats soft tissue lesions, having already performed more than 45,000 procedures to date. Meanwhile, the Monarch platform — the first robotic-assisted bronchoscopy system introduced in the U.S. — offers reach into the periphery of the lung with continuous real-time vision, precision and control.

“Through our commitment to transform patients’ lives, Johnson & Johnson is advancing innovativ…

Read more
  • 0